

PENT COOPERATION TREATY

PCT

REC'D 13 DEC 2004

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PCT 21204	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US03/30161	International filing date (day/month/year) 23 September 2003 (23.09.2003)	Priority date (day/month/year) 27 September 2002 (27.09.2002)
International Patent Classification (IPC) or national classification and IPC IPC(7): C07D 239/28, 239/34, 239/36, 239/47, 239/48, 239/52, 239/58; A61K 31/505, 31/506; A61P 25/18, 25/28 and US Cl.: 544/ 309, 310, 315, 316, 319, 320, 326; 514/ 256, 269, 275		
Applicant MERCK & CO., INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 3 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:
 - I Basis of the report
 - II Priority
 - III Non-establishment of report with regard to novelty, inventive step and industrial applicability
 - IV Lack of unity of invention
 - V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI Certain documents cited
 - VII Certain defects in the international application
 - VIII Certain observations on the international application

Date of submission of the demand 24 March 2004 (24.03.2004)	Date of completion of this report 06 November 2004 (06.11.2004)
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer DEBORAH A. THOMAS Venkataraman Balasubramanian Telephone No. (571) 272-1600 PARALEGAL SPECIALIST GROUP 1000 <i>[Signature]</i>

Form PCT/IPEA/409 (cover sheet)(July 1998)

BEST AVAILABLE COPY

I. Basis of the report**1. With regard to the elements of the international application:***

the international application as originally filed.

the description:
 pages 1-158, as originally filed
 pages NONE, filed with the demand
 pages NONE, filed with the letter of _____.

the claims:
 pages 159-180, as originally filed
 pages NONE, as amended (together with any statement) under Article 19
 pages NONE, filed with the demand
 pages NONE, filed with the letter of _____.

the drawings:
 pages NONE, as originally filed
 pages NONE, filed with the demand
 pages NONE, filed with the letter of _____.

the sequence listing part of the description:
 pages NONE, as originally filed
 pages NONE, filed with the demand
 pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
 the language of publication of the international application (under Rule 48.3(b)).
 the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

contained in the international application in printed form.
 filed together with the international application in computer readable form.
 furnished subsequently to this Authority in written form.
 furnished subsequently to this Authority in computer readable form.
 The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

the description, pages NONE
 the claims, Nos. NONE
 the drawings, sheets/fig NONE

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>1-23</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>10-23</u>	YES
	Claims <u>1-9</u>	NO
Industrial Applicability (IA)	Claims <u>1-23</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-23 meet the criteria set out in PCT Article 33(2), because the prior art does not teach the compound of formula I, its composition and method of use embraced in claims 1-23.

Claims 1-9 lack an inventive step under PCT Article 33(3) as being obvious over Fitzjohn et al., US 5,684,011. Fitzjohn et al., teaches several pyrimidine compounds which include generically pyrimidine compounds claims in the instant claims. See formula I and note the definition of various variable groups. See Table 1 for examples of compounds made shown on column 8 through 12. Fitzjohn et al., does not show examples of instant compounds. However, Fitzjohn et al. teaches equivalency of exemplified compounds with those claimed in the definition of various variable groups of compound of formula I. Thus it would be have been obvious to one trained in the art at the time of the invention to make variously substituted pyrimidines including instant pyrimidines as taught by Fitzjohn et al., in view of equivalency teaching taught by the reference.

Claims 1-9 lack an inventive step under PCT Article 33(3) as being obvious over Meyer et al., US 2002/0004600. Meyer et al., teaches process for making several pyrimidine compounds which include generically pyrimidine compounds claims in the instant claims. See formula I and note the definition of various variable groups. See examples 1-17 of compounds made shown on page 3 through 5.

Meyer et al., does not show examples of instant compounds. However, Meyer et al. teaches equivalency of exemplified compounds with those claimed in the definition of various variable groups of compound of formula I. Thus it would be have been obvious to one trained in the art at the time of the invention to make variously substituted pyrimidines including instant pyrimidines as taught by Fitzjohn et al., in view of equivalency teaching taught by the reference.

Claims 10-23 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not fairly suggest the method of use embraced in the instant claims.

Claims 1-23 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry as therapeutic agents for treating several diseases including obesity.